Coronary Artery Disease News and Research

Latest Coronary Artery Disease News and Research

Data shows increased risk of heart attack, stroke for patients having high blood pressure

For patients with diabetes and heart disease, less isn't always more - at least when it comes to blood pressure.

15 Mar 2010

BDNF could someday play significant role in prevention of high blood pressure: Study

Researchers at Oregon Health & Science University's School of Dentistry (www.ohsu.edu/sod) have discovered that nitric oxide is a powerful regulator of a molecule that plays a critical role in the development and function of the nervous system. The finding could someday play a significant role in the prevention and treatment of high blood pressure, which affects about one in three adults in the United States.

12 Mar 2010

Following existing cholesterol-lowering target guidelines can prevent more heart disease-related incidents

Only half of all patients at high risk of heart disease are given correct targets for lowering their cholesterol levels according to a study of 25,250 patients in Germany published online today (Thursday 11 March) in the European Heart Journal.

11 Mar 2010

Adherence to lipid-lowering guidelines may help reduce cardiovascular deaths

11 Mar 2010

Bristol-Myers Squibb, AstraZeneca commence SAVOR-TIMI 53 trial of ONGLYZA for type 2 diabetes

Bristol-Myers Squibb Company and AstraZeneca today announced the commencement of the “Saxagliptin Assessment of Vascular Outcomes Recorded in Patients with Diabetes Mellitus” trial, a multicenter, randomized, double-blind, placebo-controlled Phase 4 study, to evaluate treatment with ONGLYZA™ (saxagliptin), a dipeptidyl peptidase-4 inhibitor, in adult type 2 diabetes patients with cardiovascular risk factors.

10 Mar 2010

New data for BMS747158 to be featured in oral presentation at ACC Annual Scientific Session 2010

Lantheus Medical Imaging, Inc., a worldwide leader in diagnostic imaging, today announced that new data for BMS747158, the company’s novel drug candidate in clinical development as a Positron Emission Tomography (PET) perfusion imaging agent, will be featured in an oral presentation at the American College of Cardiology 59th Annual Scientific Session taking place March 14-16, 2010 in Atlanta.

10 Mar 2010

Bilateral oophorectomy may do more harm than good

Removal of the ovaries (bilateral oophorectomy) while performing a hysterectomy is common practice to prevent the subsequent development of ovarian cancer. This prophylactic procedure is performed in 55% of all U.S. women having a hysterectomy, or approximately 300,000 times each year. An article in the March/April issue of The Journal of Minimally Invasive Gynecology suggests that this procedure may do more harm than good.

10 Mar 2010

Bypass surgery: New method of growing arteries could lead to non-invasive option for treatment

A new method of growing arteries could lead to a "biological bypass"-or a non-invasive way to treat coronary artery disease, Yale School of Medicine researchers report with their colleagues in the April issue of Journal of Clinical Investigation.

9 Mar 2010

Atherotech to exhibit VAP Cholesterol Test at ACC 2010

Atherotech Inc. today announced it will be presenting research in two poster sessions and exhibiting its VAP® Cholesterol Test in booth #1311 at the American College of Cardiology (ACC) 59th Annual Scientific Session Exposition. The annual meeting takes place March 14-16, 2010, at the Georgia World Congress Center in Atlanta.

9 Mar 2010

Rcadia Medical Imaging receives CE Mark for COR Analyzer System

Rcadia Medical Imaging today announced that it has received a CE Mark for the COR Analyzer® System, its proprietary software that helps identify patients with significant CAD (Coronary Artery Disease) by a fully automatic analysis of coronary CT angiography (cCTA) studies. The CE Mark allows the company to market the system in the European Union and other countries that accept the CE Mark registration. The COR Analyzer is marketed in the U.S. under 510(k) clearance and Rcadia was named 2009 Best New Radiology Vendor by AuntMinnie.com.

8 Mar 2010

Anthera Pharmaceuticals' 6.0M common stock public offering: Merriman Curhan Ford acts as co-manager

Merriman Curhan Ford Group, Inc. was a co-manager in Anthera Pharmaceuticals, Inc.'s public offering of 6.0 million shares of common stock.

6 Mar 2010

Anthera Pharmaceuticals completes initial public offering at $7.00 per share

Anthera Pharmaceuticals, Inc., a biopharmaceutical company developing drugs to treat serious diseases associated with inflammation, today announced the completion of its initial public offering of six million shares of common stock at a price of $7.00 per share. The net proceeds of the offering to Anthera, after deducting underwriting discounts and commissions and estimated offering expenses payable by Anthera, were approximately $36.7 million.

5 Mar 2010

RMR can non-invasively, quickly and accurately detect presence of sCAD

Newly published data shows using a Respiratory Modulation Response (RMR) is a novel, non-invasive measure to quickly and accurately detect the presence of significant coronary artery disease (sCAD). Patients in the study with sCAD had a lower RMR compared to patients without, regardless of their risk factors or clinical history of angina, previous myocardial infarction (MI), or angioplasty.

3 Mar 2010

Evolving sex disparity in midlife stroke prevalence: Further study needed

When it comes to stroke prevalence, it appears that the gender gap is widening. According to a new report from a researcher at the Keck School of Medicine of the University of Southern California (USC), women between the ages of 35 and 64 are almost three times more likely to have a stroke compared to men in the same age group.

26 Feb 2010

Resverlogix commences enrollment in RVX-208 Phase 2 clinical trial for atherosclerosis in ACS patients

Resverlogix Corp. announced today that it has officially activated the first site for the ASSURE 1 trial and commenced enrollment of patients for dosing of RVX-208. ASSURE 1 is the second Resverlogix Phase 2 clinical trial, led by Cleveland Clinic. This trial will examine RVX-208, Resverlogix's oral small molecule therapy for the treatment of atherosclerosis, in patients with acute coronary syndrome (ACS). This preparatory acute coronary syndrome study will ensure that 50 percent of the enrolled patients receive the IVUS (intravascular ultrasound) assessment.

26 Feb 2010

BioMedix Vascular Solutions, Howard University Hospital to participate in Community Health Project and Demonstration

BioMedix Vascular Solutions, Inc. announced today that the company has partnered with Howard University Hospital, Department of Surgery to participate in a Community Health Project and Demonstration focused on diagnosing and treating the potentially life-threatening condition called Peripheral Arterial Disease (PAD).

25 Feb 2010

Stereotaxis' revenue for recent fourth-quarter increases 16%

Stereotaxis, Inc. today reported its financial results for the quarter and the year ended December 31, 2009. Revenue for the recent fourth quarter grew 16% to $14.1 million compared with $12.1 million in the same quarter a year ago.

25 Feb 2010

BioMedix Vascular Solutions, Howard University Hospital partner to help uninsured PAD patients

24 Feb 2010

New treatments for heart disease

Two studies published in the latest issue of Cell Transplantation (18:12) may lead to new treatments for the treatment of heart diseases. The first study, carried out by a team of Brazilian researchers, found that cell transplantation of bone marrow mononuclear cells (BMMCs) directly into the heart benefited patients suffering from refractory angina.

24 Feb 2010

Forest Laboratories' Bystolic tablets for treatment of stable CHF failed to receive FDA approval

Forest Laboratories, Inc. announced today that the U.S. Food and Drug Administration did not approve the additional indication for Bystolic® (nebivolol) tablets as a treatment for stable chronic heart failure (CHF) as requested in the company’s Supplemental New Drug Application (sNDA).

23 Feb 2010

Coronary Artery Disease News and Research

Latest Coronary Artery Disease News and Research

Data shows increased risk of heart attack, stroke for patients having high blood pressure

BDNF could someday play significant role in prevention of high blood pressure: Study

Following existing cholesterol-lowering target guidelines can prevent more heart disease-related incidents

Adherence to lipid-lowering guidelines may help reduce cardiovascular deaths

Bristol-Myers Squibb, AstraZeneca commence SAVOR-TIMI 53 trial of ONGLYZA for type 2 diabetes

New data for BMS747158 to be featured in oral presentation at ACC Annual Scientific Session 2010

Bilateral oophorectomy may do more harm than good

Bypass surgery: New method of growing arteries could lead to non-invasive option for treatment

Atherotech to exhibit VAP Cholesterol Test at ACC 2010

Rcadia Medical Imaging receives CE Mark for COR Analyzer System

Anthera Pharmaceuticals' 6.0M common stock public offering: Merriman Curhan Ford acts as co-manager

Anthera Pharmaceuticals completes initial public offering at $7.00 per share

RMR can non-invasively, quickly and accurately detect presence of sCAD

Evolving sex disparity in midlife stroke prevalence: Further study needed

Resverlogix commences enrollment in RVX-208 Phase 2 clinical trial for atherosclerosis in ACS patients

BioMedix Vascular Solutions, Howard University Hospital to participate in Community Health Project and Demonstration

Stereotaxis' revenue for recent fourth-quarter increases 16%

BioMedix Vascular Solutions, Howard University Hospital partner to help uninsured PAD patients

New treatments for heart disease

Forest Laboratories' Bystolic tablets for treatment of stable CHF failed to receive FDA approval

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Coronary Artery Disease News and Research

Latest Coronary Artery Disease News and Research

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Newsletters you may be interested in